SOPHiA GENETICS and Myriad Genetics collaborate on prostate cancer genomic instability score, with AstraZeneca involved

SOPHiA GENETICS and Myriad Genetics announced a collaboration to develop a prostate cancer-specific genomic instability score, extending Myriad's push into precision oncology. AstraZeneca is also involved in the partnership.

Detected & updated continuously · Source: Nebula